A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
About this trial
This is an interventional supportive care trial for Chronic Myeloproliferative Disorders focused on measuring psychosocial effects of cancer and its treatment, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent/refractory childhood Hodgkin lymphoma, accelerated phase chronic myelogenous leukemia, atypical chronic myeloid leukemia, BCR-ABL negative, blastic phase chronic myelogenous leukemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, juvenile myelomonocytic leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, childhood myelodysplastic syndromes, primary myelofibrosis, de novo myelodysplastic syndromes, disseminated neuroblastoma, myelodysplastic/myeloproliferative neoplasm, unclassifiable, previously treated childhood rhabdomyosarcoma, previously treated myelodysplastic syndromes, recurrent childhood rhabdomyosarcoma, recurrent neuroblastoma, recurrent ovarian germ cell tumor, secondary myelodysplastic syndromes
Eligibility Criteria
DISEASE CHARACTERISTICS:
Disease indications for hematopoietic stem cell transplantation (HSCT)
- All transplant types allowed
- Scheduled to receive HSCT within the next 30 days
PATIENT CHARACTERISTICS:
- Dyad consisting of age-eligible child and parent
Child patient with an "accompanying parent" who consents to participate
"Accompanying parent" is defined as the parent/legal guardian who physically stays with the recipient during the initial HSCT hospitalization and plans to be present during the follow-up assessments
If the responsibility for care giving is shared, parents will designate who will participate (i.e., as study participant)
- No substitutions are permitted once this decision has been made
- Accompanying parent must be ≥ 18 years old
- Possesses a working knowledge of English
- Able to sign consent/assent to participate
PRIOR CONCURRENT THERAPY:
- No concurrent participation in another quality-of-life intervention study
Sites / Locations
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
- Cincinnati Children's Hospital Medical Center
- Children's Hospital of Philadelphia
- Fred Hutchinson Cancer Research Center
- Medical College of Wisconsin Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm I
Arm II
Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site. The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant.
Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).